How to take the targeted drug Osimertinib (Tagrisso) correctly and ensure its efficacy

Osimertinib is a third-generation EGFR targeted drug, mainly used to treat the presence of EGFR Patients with mutated non-small cell lung cancer (NSCLC), especially those with T790M drug-resistant mutations, have a significant effect. The drug blocks the signaling pathway by irreversibly binding to the mutated EGFR receptor, thereby inhibiting the proliferation and metastasis of tumor cells. Clinical data shows that osimertinib can effectively prolong progression-free survival and overall survival, making it the main treatment option for first-line and drug-resistant EGFR mutated lung cancer. To fully realize its efficacy, correct administration and medication compliance are crucial.

The standard recommended dose is 80mg once a day, which can be taken in the morning or evening. It is usually recommended to take the medicine at a fixed time every day to maintain a stable blood concentration. Osimertinib can be taken with or without food, but should be avoided with foods that affect metabolism such as grapefruit juice. If the patient has difficulty swallowing, he can stir the tablets into half a cup of non-carbonated water, take them immediately after the tablets are completely disintegrated, and rinse the cup with the same amount of water before drinking. It should be noted that the tablets should not be crushed or heated to avoid damaging the stability of the drug. If you miss a dose, you should take it as soon as possible. However, if it is less than 12 hours before the next dose, skip the missed dose and do not take it again.

To ensure the efficacy, patients need to take osimertinib regularly for a long time and should avoid interruption or reduce the dose on their own. Some patients may experience minor adverse reactions during the early stages of treatment, such as rash, diarrhea, stomatitis, or fatigue. These are usually controllable side effects. Doctors will adjust the dose or perform symptomatic treatment according to the patient's tolerance, and should not stop medication at will. Studies have shown that treatment maintained for a sufficient period of time not only sustainably inhibits tumor growth, but can also effectively delay the emergence of drug resistance. If you continuously miss doses or stop the medication without authorization, the drop in blood concentration will weaken the efficacy and may lead to tumor progression.

In addition, patients should undergo regular imaging review and liver and kidney function monitoring while taking the drug to ensure that the drug works within a safe range. If serious adverse reactions occur, such as dyspnea, interstitial pneumonia or abnormal heart rhythm, seek medical attention immediately and suspend medication. A reasonable diet, adequate rest and following doctor's instructions are the keys to ensuring curative effect. Generally speaking, as a highly effective EGFR targeting drug, the efficacy of osimertinib not only depends on the characteristics of the drug itself, but also depends on the patient's implementation of medication specifications and persistence in long-term treatment.

Reference materials:https://www.drugs.com/